...
首页> 外文期刊>Pain research & management: the journal of the Canadian Pain Society = journal de la socie?te? canadienne pour le traitement de la douleur >Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
【24h】

Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution

机译:谭白菊,5-羟色氨酸和镁(Aurastop)与单独镁对Aura现象的影响及其演变的比较

获取原文
           

摘要

None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura.Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated.In the setting of a single-center, pilot, clinical trial, we aimed at comparing the effects of Aurastop (a combination of tanacetumparthenium (150 mg extracted at 0.8% ? 1.2 mg di of active parthenolide), griffonia simplicifoila (20 mg of 5-hydroxy tryptophan),and magnesium (185 mg of magnesium pidolatum)) with those of magnesium alone (2.25 grams/tablet, corresponding to 184 mgof Mg++) in the treatment of acute attacks of migraine with aura. Between June 2017 and June 2018, 50 consecutive patients (27/23male/female; mean age, 31 [18–57] years) with at least 3 episodes of aura per year were included (t0). Participants were instructedto keep track of the following 4 episodes of migraine with aura (t1) and invited to assume (1) a tablet of Aurastop at the beginningof the following 2 episodes of aura and (2) a magnesium tablet alone at the occurrence of the third and fourth aura attacks. Fortyeightpatients (96.0%) had 50% reduction in aura duration when treated with Aurastop vs. 7 patients (14.0%) when treated withmagnesium alone (p 0.001); 48 patients (96.0%) had 50% reduction of aura-related disability when receiving Aurastop vs. 5patients (10.0%) when treated with magnesium alone (p 0.001); however, patients receiving Aurastop did not need to take painkillers in 35% of aura attacks vs. 3% when assuming magnesium (p 0.001). ,ese results support the hypothesis that Aurastopmight be effective in interfering with the phenomenon of aura and provide evidence that the clinical benefit attributable to thiscombination of molecules might be greater than that obtained with single compounds of proven effect on the biology of migraine.
机译:迄今为止,关于偏头痛的临床试验均未集中于调节先兆现象的可能性。此外,对先兆的适当管理是否能更好地控制头痛期的研究还很少。中心,中试,临床试验,我们旨在比较Aurastop(联合使用tanacetumparthenium(150 mg提取物,含量为0.8%的1.2 mg苯二酚),griffonia simplicifoila(20 mg 5-羟基色氨酸)和镁的影响(185 mg羊油镁)与单独的镁(2.25克/片,相当于184 mg Mg ++)用于治疗先兆性偏头痛的急性发作。在2017年6月至2018年6月之间,纳入了50例每年至少发生3次先兆发作的连续患者(27/23男/女;平均年龄31 [18-57]岁)(t0)。要求参与者跟踪随后的4次伴有先兆的偏头痛发作(t1),并邀请他们假设(1)在随后的2次先兆发作开始时服用Aurastop片,以及(2)在发生先兆时先服用镁片。第三和第四光环攻击。接受Aurastop治疗的48位患者(96.0%)的光晕持续时间减少了50%以上,而仅接受镁治疗的7位患者(14.0%)减少了(p <0.001);接受Aurastop治疗时,有48例(96.0%)的先兆相关残疾减少了> 50%,而单独使用镁治疗的患者为5例(10.0%)(p <0.001);但是,接受Aurastop的患者在35%的先兆发作中无需服用止痛药,而在服用镁的情况下则为3%(p <0.001)。这些结果支持了先兆终止可能有效地干扰先兆现象的假设,并提供了证据表明,这种分子结合所产生的临床益处可能大于对偏头痛生物学已证明有效的单一化合物所获得的临床益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号